Cerus Corporation (NASDAQ:CERS) Enters Into A Deal With The Community Blood Center


Cerus Corporation (NASDAQ:CERS) reported that it has finalized a purchase deal for the INTERCEPT Blood System for plasma and platelets, turning into the first blood center located in Wisconsin to promise for implementation of pathogen reduction system. CBC provides blood components to as many as seventeen hospitals in Wisconsin state and Michigan, distributing nearly 11,500 plasma and 13,500 platelet units annually.

The expert speaks

John Hagins, the CEO and President of CBC, said that providing reliable and safe blood components to the patients and hospitals in the community is of top priority for the company. Intercept will enable the company to take a proactive step against transfusion-transmitted infections, finalizing an association with Cerus as an evident choice.William “Obi” Greenman, the Chief Executive Officer and President of Cerus, said that the blood components offered by CBC are important to the hospitals community they serve. The management is delighted that they have selected to install the Intercept Blood System to ensure that the plasma and platelet components reaching patients are of best safety standard available.

Community Blood Center

The Community Blood Center offers 100% of the blood utilized by patients in eighteen hospitals in Michigan and Wisconsin, with neighborhood donor centers in Little Chute, Woodruff, Appleton and Oshkosh.In 2014, volunteer donors donated over 50,000 blood donations in association with the non-profit group. CBC has been committed to offering areliable, safe blood supply for hospital patients and it is a member of America’s Blood Centers.

The profile

Cerus Corporation (NASDAQ:CERS) comes in the list of biomedical products firms focused in the industry of blood transfusion safety. Its “INTERCEPT” Blood System is developed to minimize the perils of transfusion-transmitted infections by disabling pathogens such as parasites, viruses and bacteria that may be there in donated blood. The nucleic acid aimingprocedure of action of the Cerus “INTERCEPT” treatment is developed to inactivate set transfusion threats.